CD274 and glioblastoma: In 2021, a multicohort phase 1b KEYNOTE-028 study (NCT02054806) comparing Pembrolizumab to PD-L1 positive GBM found that Pembrolizumab monotherapy promoted durable antitumor activity with a median PFS of 2.8 months and a median OS of 13.1 months.